The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to the United States Department of Health and Human Services. Some federal ...
After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade ...
Drugmaker Amneal Pharmaceuticals with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court ...
Policy differences are endemic in politics, and the phrase "causing more heat than light" regarding federal drug policy comes readily to mind listening to the rhetoric coming from the Federal ...
Opinion: Customers expected to do business and make money in Spanish, but English-language contract language misled them.
In a significant ruling, the United States District Court for the District of New Jersey has ordered that Teva’s inhaler ...
Democrats have hit on a new tactic in their long battle with drug companies: challenge patents that they say are deliberate attempts to game the system and box out low-cost, generic competitors.
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to the United States Department of Health and Human Services. Some federal ...
With the backing of the U.S. Federal Trade Commission, Amneal convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical patents from a Food and Drug Administration list of ...
Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, and those can be pretty expensive. But the FTC hasn’t announced if ...